340 related articles for article (PubMed ID: 34493144)
1. Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States.
Jain SS; Li SS; Xie J; Sutton MB; Fine JT; Edelberg JM; Gao W; Spertus JA; Cohen DJ
J Med Econ; 2021; 24(1):1115-1123. PubMed ID: 34493144
[TBL] [Abstract][Full Text] [Related]
2. Costs and Healthcare Resource Utilization for Obstructive Hypertrophic Cardiomyopathy With Septal Reduction Therapy.
Butzner M; Maron MS; Sarocco P; Teng CC; Stanek E; Tan H; Robertson LA
J Invasive Cardiol; 2022 Dec; 34(12):E866-E872. PubMed ID: 36288089
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization and cost of obstructive hypertrophic cardiomyopathy in a US population.
Butzner M; Maron M; Sarocco P; Teng CC; Stanek E; Tan H; Robertson L
Am Heart J Plus; 2022 Jan; 13():100089. PubMed ID: 38560082
[TBL] [Abstract][Full Text] [Related]
4. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
5. Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States.
Naidu SS; Sutton MB; Gao W; Fine JT; Xie J; Desai NR; Owens AT
J Med Econ; 2023; 26(1):682-690. PubMed ID: 37170479
[TBL] [Abstract][Full Text] [Related]
6. Healthcare resource utilization and cost among individuals with late-onset versus adult-onset Huntington's disease: a claims‑based retrospective cohort study.
To TM; Ta JT; Patel AM; Arndorfer S; Abbass IM; Gandhy R
J Med Econ; 2023; 26(1):862-870. PubMed ID: 37350423
[TBL] [Abstract][Full Text] [Related]
7. Direct health care costs associated with COVID-19 in the United States.
DeMartino JK; Swallow E; Goldschmidt D; Yang K; Viola M; Radtke T; Kirson N
J Manag Care Spec Pharm; 2022 Sep; 28(9):936-947. PubMed ID: 35722829
[No Abstract] [Full Text] [Related]
8. The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States.
Woolley M; Cook EE; Mu F; Betts KA; Billmyer E; Yim E; Chen J; Wu EQ
Adv Ther; 2022 Aug; 39(8):3547-3559. PubMed ID: 35689161
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United States.
Desai NR; Sutton MB; Xie J; Fine JT; Gao W; Owens AT; Naidu SS
Am J Cardiol; 2023 Apr; 192():16-23. PubMed ID: 36709525
[TBL] [Abstract][Full Text] [Related]
10. Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database Study.
Owens AT; Sutton MB; Gao W; Fine JT; Xie J; Naidu SS; Desai NR
Cardiol Ther; 2022 Jun; 11(2):249-267. PubMed ID: 35230625
[TBL] [Abstract][Full Text] [Related]
11. Health Care Utilization and Economic Burden in Patients with Central Precocious Puberty: An Assessment of the Commercially Insured and Medicaid Populations.
Klein K; Soliman AM; Bonafede M; Nelson JK; Grubb E
J Manag Care Spec Pharm; 2019 Jul; 25(7):836-846. PubMed ID: 31232203
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of alcohol septal ablation in mildly symptomatic or severely symptomatic patients with hypertrophic obstructive cardiomyopathy].
Sun JJ; Li PJ; Yu XP; Zhao H; Zhang XL; Tu CC; Zhang MD; Jiang TY; Song XT; He JQ
Zhonghua Xin Xue Guan Bing Za Zhi; 2023 May; 51(5):513-520. PubMed ID: 37198123
[No Abstract] [Full Text] [Related]
13. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
Campbell A; Cong Z; Agodoa I; Song X; Martinez DJ; Black D; Lew CR; Varker H; Chan C; Lanzkron S
J Manag Care Spec Pharm; 2020 Sep; 26(9):1121-1129. PubMed ID: 32597290
[TBL] [Abstract][Full Text] [Related]
14. Burden of influenza in patients with cardiovascular disease who receive antiviral treatment for influenza.
Corral M; Castro RC; To TM; Arndorfer S; Wang S; Stephens J
J Med Econ; 2022; 25(1):1061-1067. PubMed ID: 35943115
[TBL] [Abstract][Full Text] [Related]
15. Comparative Assessment of Medical Resource Use and Costs Associated with Patients with Symptomatic Peripheral Artery Disease in the United States.
Chase MR; Friedman HS; Navaratnam P; Heithoff K; Simpson RJ
J Manag Care Spec Pharm; 2016 Jun; 22(6):667-75. PubMed ID: 27231794
[TBL] [Abstract][Full Text] [Related]
16. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes.
Weir MR; Chen YW; He J; Bookhart B; Campbell A; Ashton V
Diabetes Ther; 2021 Dec; 12(12):3167-3186. PubMed ID: 34699020
[TBL] [Abstract][Full Text] [Related]
17. Impact of Pain Severity and Opioid Use on Health Care Resource Utilization and Costs Among Patients with Knee and Hip Osteoarthritis.
Wei W; Gandhi K; Blauer-Peterson C; Johnson J
J Manag Care Spec Pharm; 2019 Sep; 25(9):957-965. PubMed ID: 31456495
[TBL] [Abstract][Full Text] [Related]
18. Stable Rates of Obstructive Hypertrophic Cardiomyopathy in a Contemporary Era.
Butzner M; Leslie DL; Cuffee Y; Hollenbeak CS; Sciamanna C; Abraham T
Front Cardiovasc Med; 2021; 8():765876. PubMed ID: 35071348
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and patient journey of Rett syndrome in the United States: a real-world evidence study.
May D; Kponee-Shovein K; Mahendran M; Downes N; Sheng K; Lefebvre P; Cheng WY
BMC Neurol; 2023 Apr; 23(1):141. PubMed ID: 37016355
[TBL] [Abstract][Full Text] [Related]
20. Real-World Evaluation of Direct and Indirect Economic Burden Among Endometriosis Patients in the United States.
Soliman AM; Surrey E; Bonafede M; Nelson JK; Castelli-Haley J
Adv Ther; 2018 Mar; 35(3):408-423. PubMed ID: 29450864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
